Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer

Jun Du | Yundi Zhang | Yiting Dong | Jianchun Duan | Hua Bai | Jie Wang | Jiachen Xu | Zhijie Wang

1Office of Academic Research, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Correspondence
Jiachen Xu and Zhijie Wang, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17, Panjiayuanwenti, Chaoyang District, Beijing 100021, China.
Email: xjcwelcome@126.com and jie_969@163.com

Funding information
Beijing Hope Run Special Fund of Cancer Foundation of China, Grant/Award Number: LC2020B09; National Natural Sciences Foundation, Grant/Award Numbers: 81871889, 82072586; Natural Science Foundation of Beijing Municipality, Grant/Award Number: 7212084; the Special Research Fund for Central Universities, Peking Union Medical College, Grant/Award Number: 3332021029

Abstract

Background: With the improvement of therapeutic strategies from cytotoxic chemotherapy to immunotherapy, the possibility of achieving timely intervention for lung cancer has dramatically increased. This study aimed to systematically evaluate the reporting quality of randomized controlled trials (RCT) on immunotherapy in lung cancer.

Methods: The RCTs evaluating the efficacy of immunotherapy in lung cancer published up to 2021 were searched and collected from PUBMED and EMBASE by two investigators. The 2010 Consolidated Standards for Test Reports (CONSORT) statement-based 28-point overall quality score (OQS) and the 2001 CONSORT statement-based 19-point OQS was utilized for assessing the overall quality of each report.

Results: One hundred and fifty-two related RCTs were retrieved in this study, including 81,931 patients. The average OQS in 2010 was 17.89 (range, 7.5–24.5). Overall, studies have sufficiently reported the eligibility criteria (143/152; 94.07%), described the scientific background (150/152; 98.7%) and discussed interventions (147/152; 96.7%). However, the RCTs did not consistently report the changes to trial after commencement (48/152; 31.6%), allocation, enrollment and assignment personnel (34/152; 22.4%), blinding (48/152; 31.6%), or randomization method (58/152; 38.2%).

Conclusions: The overall reporting quality of RCTs on immunotherapy in lung cancer was found to be unsatisfactory despite the fact that the CONSORT statement was issued more than a decade ago. Furthermore, there was virtual selectivity and heterogeneity in reporting some key issues in these trials. This is the first study to enlighten lung cancer researchers especially focusing on immunotherapy, and also to remind editors and peer reviewers to strengthen their due diligence.

KEYWORDS
CONSORT statement, immunotherapy, lung cancer, randomized controlled trial, reporting quality

INTRODUCTION

The gold standard of evidence-based medicine is still randomized controlled trials (RCTs), and the reporting quality of RCTs is crucially important for guiding clinical practice.1,2 The most significant and immediate resource for evaluating trial quality is the published RCTs. In order to ensure the transparency and clarity of the trial report, the Consolidated Standards of Reporting Trials (CONSORT) statement was formulated, which was subsequently updated in 2001 and 2010.3

As one of the most lethal solid cancers in the world, lung cancer patients, 95% of which are classified as non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC),4–8
exhibited poor clinical outcome when diagnosed with stage IV, making early intervention extremely crucial. Fortu-
nately, with the deeper understanding of molecular genetics and the immune microenvironment, therapeutic strategies have advanced from pure cytotoxic chemotherapy to targeted therapy and, most recently, immunotherapy. Several antiprogrammed death receptor-1 (PD-1)/PD-ligand-1 (PD-L1) antibodies have presented inspiring and long-lasting benefit in driver gene-negative NSCLCs in either setting of monotherapy or combined therapy, and also exhibited encouraging efficacy in some settings of SCLCs, many of which have already been included in the international and domestic guidelines.

Therefore, it is very important to evaluate the reporting quality of RCTs on immunotherapy in lung cancer, since those which are poorly reported will bring adverse effect to clinical practice. In this study, we aimed to evaluate the reporting quality of published RCTs on immunotherapy in lung cancer on the basis of the CONSORT statement.

METHODS

Study selection

This study was driven by a transcendental, written plan (see supplementary methods). To determine the human prospective randomized controlled trials, we searched the all-sided English literature published in PUBMED and EMBASE, with the search conditions: (“lung cancer”, “randomized” and “immunotherapy”) OR (“lung cancer”, “randomized” and “PD-1”) OR (“lung cancer”, “randomized” and “PD-L1”) OR (“lung cancer”, “randomized” and “pembrolizumab”) OR (“lung cancer”, “randomized” and “nivolumab”) OR (“lung cancer”, “randomized” and “toripalimab”) OR (“lung cancer”, “randomized” and “tislelizumab”) OR (“lung cancer”, “randomized” and “sintilimab”) OR (“lung cancer”, “randomized” and “atumolizumab”) OR (“lung cancer”, “randomized” and “atezolizumab”) OR (“lung cancer”, “randomized” and “toripalimab”) OR (“lung cancer”, “randomized” and “tislelizumab”) OR (“lung cancer”, “randomized” and “sintilimab”) OR (“lung cancer”, “randomized” and “atumolizumab”) OR (“lung cancer”, “randomized” and “atezolizumab”) OR (“lung cancer”, “randomized” and “toripalimab”) OR (“lung cancer”, “randomized” and “tislelizumab”) OR (“lung cancer”, “randomized” and “sintilimab”) OR (“lung cancer”, “randomized” and “atumolizumab”) OR (“lung cancer”, “randomized” and “atezolizumab”) OR (“lung cancer”, “randomized” and “toripalimab”) OR (“lung cancer”, “randomized” and “tislelizumab”) OR (“lung cancer”, “randomized” and “sintilimab”)).

OR (“lung cancer”, “randomized” and “camrelizumab”)

OR (“lung cancer”, “randomized” and “durvalumab”) as of January 2021 in Pubmed. We searched EMBASE by following: #1 durvalumab OR immunotherapy OR atezolizumab OR toripalimab OR tislelizumab OR sintilimab OR camrelizumab, #2 “lung cancer” AND immunotherapy, “#1 AND #2” was our final terms. This study excluded pediatric participants.

Reporting quality assessment

The data for each publication was reviewed and extracted by two well-trained investigators. A standardized evaluation checklist was used to compare the results of each test. The 2010 and 2001 CONSORT standard were both applied for comparison experiments. What is more, detailed assessment of key methodological factors, endpoints, follow-up, subgroup analyses and adverse events were also conducted. Each item in the standard list was divided into completed or incomplete. (Supplementary methods).

Data collection

The criteria of each study were evaluated and entered into a dedicated electronic research database by two observers. Including the first three CONSORT evaluations of each observer, a pilot study was carried out which arbitrated the results to guarantee that the interpretation of standards was agreed upon. The remainder of the studies that applied the CONSORT guidelines checklist were then arbitrated to...
correct any discrepancies between observers. An investigator analyzed the differences.

**Analysis**

In this study, the main purpose was to estimate the quality of cancer literature reports related to randomized controlled trials of lung cancer. Twenty-five categories and multiple subcategories were contained in the CONSORT standard to help explain the quality of the evidence report for any given study. Each criterion was assigned 1 point. Indicators containing two, three, or four subindices were assigned one-half, one-third, or one-quarter, respectively, to attain overall weight. This was consistent with previous studies that used similar indicators. We carried out an description of the CONSORT statement on the reporting of harms.

**Results**

In the literature search, 2038 studies were obtained. This study finally included 152 of them, as demonstrated by the flowchart in Figure 1. A total of 98 studies were excluded because they were nonlung cancer trials, and 1526 studies were excluded because they were not randomized controlled trials or randomized controlled trials assessing immunotherapy. The final 152 studies which were included were

| Characteristic                             | No. of studies | %       | 95% Lower limit | 95% Upper limit |
|--------------------------------------------|----------------|---------|-----------------|-----------------|
| **Year of publication**                    |                |         |                 |                 |
| 1976–2000                                  | 27             | 17.76   | 12%             | 24%             |
| 2001–2010                                  | 8              | 5.26    | 2%              | 9%              |
| 2011–2021                                  | 117            | 76.97   | 70%             | 84%             |
| **Region in which trials were conducted**  |                |         |                 |                 |
| Asia                                       | 28             | 18.42   | 12%             | 25%             |
| Europe and North America                   | 118            | 77.63   | 71%             | 84%             |
| Others                                     | 6              | 3.94    | 1%              | 7%              |
| **Journal**                                |                |         |                 |                 |
| Annals of Oncology                         | 10             | 6.58    | 3%              | 11%             |
| The Lancet                                 | 4              | 2.63    | 0%              | 5%              |
| Lancet Oncol                               | 19             | 12.5    | 7%              | 18%             |
| J Clin Oncol                               | 10             | 6.58    | 3%              | 11%             |
| Other journals                             | 99             | 65.13   | 58%             | 73%             |
| **Journal impact factor**                  |                |         |                 |                 |
| <4                                         | 24             | 15.79   | 10%             | 22%             |
| 4–10                                       | 45             | 29.60   | 22%             | 37%             |
| >10                                        | 83             | 54.60   | 47%             | 63%             |
| **Phase**                                  |                |         |                 |                 |
| 2                                          | 9              | 5.92    | 2%              | 10%             |
| 3                                          | 106            | 69.73   | 62%             | 77%             |
| Unclear                                    | 38             | 25      | 18%             | 32%             |
| **Intervention**                           |                |         |                 |                 |
| Immunotherapy + radiotherapy               | 3              | 1.97    | 0%              | 4%              |
| Immunochemotherapy                         | 118            | 77.63   | 71%             | 84%             |
| Comparison                                 | 33             | 21.71   | 15%             | 28%             |
| **Primary outcome**                        |                |         |                 |                 |
| Positive                                   | 130            | 85.52   | 80%             | 91%             |
| Negative                                   | 22             | 14.47   | 9%              | 20%             |
| **Sample size**                            |                |         |                 |                 |
| <200                                       | 71             | 46.71   | 39%             | 55%             |
| 200–400                                    | 16             | 10.52   | 6%              | 15%             |
| >400                                       | 65             | 42.76   | 35%             | 51%             |
subsequently divided equally into two groups for further analysis. Most of the studies took place in Asia (n = 28, 18.4%), and 77.6% (n = 118) of them were from North America and Europe (Table 1).

As shown in Figure 2, the percentages of RCTs reporting scientific background or specific objectives/hypotheses were 98.7% and 99.3%, respectively. However, the percentages of RCTs reporting blinding, random allocation mechanism and allocation, or enrollment and assignment personnel were 31.6%, 29.6%, and 22.4%, respectively.

The research characteristics and descriptive results based on the 2010 CONSORT statement are demonstrated in Table 2. The median CONSORT score was 17.89 (range, 7.5–24.5). Overall, studies sufficiently reported the eligibility criteria (143/152; 94.07%), described the scientific background (150/152; 98.7%) and discussed interventions (147/152; 96.7%). However, the RCTs did not consistently report the changes to trial after commencement (48/152; 31.6%), allocation, enrollment and assignment personnel (34/152; 22.4%), blinding (48/152; 31.6%), or randomization method (58/152; 38.2%). The evaluation based on the 2001 CONSORT statement is shown in the Table S1.

Additionally, adverse event reporting scores based on the CONSORT recommendations for harms are reported in Table S2. When clinical intervention trials are performed, it is generally unethical to “force” patients to accept a randomly assigned treatment. We would take the “advise” approach and allow patients to refuse. Then, during analysis, we analyze according to random assignment, regardless of whether we really accept the treatment plan or not, which is known as the intention to treat principle (ITT) in this study. ITT was defined as an analysis of all randomized patients in the treatment group assigned to it. If no information was provided, the RCT was considered not to have followed ITT principles (Table S3). According to our study, 41.45% of the trials followed the ITT principle. Descriptions of the use of endpoints in included trials were reported in Table S4.

**DISCUSSION**

Our study is the first quality evaluation related to immunotherapy for lung cancer. We found that although the CONSORT statement was published more than a decade ago, there are still many problems with the overall reporting quality of randomized controlled trials on immunotherapy in lung cancer.24–29

Through data analysis, the OQS of all the included trials was 17.89 (range, 7.5–24.5), indicating that the quality of the trials was not ideal. Items added or redefined in the 2010
## Table 2: Overall quality of reporting: Rating using items based on the 2010 CONSORT statement (n = 152)

| Item | Criteria | Description | No. of positive trials | % | 95% CI |
|------|----------|-------------|------------------------|---|--------|
| 1    | Title    | Identification as a randomized trial in the title | 74 | 48.68421053 | (0.407,0.566) |
| 2    | Abstract structure | Structured summary of trial design, methods, results and conclusions | 109 | 71.71052632 | (0.646,0.789) |
| 3    | Background | Structured summary of trial design, methods, results and conclusions | 150 | 98.68421053 | (0.969,1.005) |
| 4    | Objectives | Description of the specific objectives or the scientific hypotheses in the introduction | 151 | 99.34210526 | (0.981,1.006) |
| 5    | Trial design | Description of trial design, including allocation ratio | 134 | 88.15789474 | (0.830,0.933) |
| 6    | Participants | Description of the eligibility criteria for participants | 143 | 94.07894737 | (0.903,0.978) |
| 7    | Settings and location | Description of the settings and locations where the data were collected | 97 | 63.81578947 | (0.562,0.715) |
| 8    | Interventions | Details of the interventions intended for each group | 147 | 96.71052632 | (0.939,0.995) |
| 9    | Outcomes | Definition of primary and secondary outcome measures, including how and when they were assessed | 146 | 96.05263158 | (0.930,0.991) |
| 10   | Sample size | Description of sample size calculation | 112 | 73.68421053 | (0.667,0.807) |
| 11   | Randomization, sequence generation | Definition of the method used to generate the random allocation sequence | 58 | 38.15789474 | (0.304,0.459) |
| 12   | Randomization, restriction | Description of the type of randomization; details of any restriction | 83 | 54.60526316 | (0.467,0.625) |
| 13   | Allocation concealment | Description of the mechanism used to implement the random allocation sequence to assure concealment until interventions were assigned | 45 | 29.60526316 | (0.223,0.369) |
| 14   | Implementation | Description of who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | 34 | 22.36842105 | (0.157,0.290) |
| 15   | Blinding | Whether or not participants, those administering the interventions, or those assessing the outcomes were blinded to group assignment; if relevant, description of the similarity of interventions | 48 | 31.57894737 | (0.242,0.390) |
| 16   | Statistical methods | Description of the statistical methods used to compare groups for primary and secondary outcomes | 130 | 85.52631579 | (0.799,0.911) |
| 17   | Ancillary analysis, method | Description of the methods for additional analyses, such as subgroup analyses and adjusted analyses | 104 | 68.42052625 | (0.610,0.758) |
| 18   | Diagram | A CONSORT diagram was presented to show the flow of participants | 0 | 0 | |
| 19   | Participant flow | Details on the flow of participants through each stage of the trials (number of patients randomly assigned, receiving intended treatment, and were analyzed for the primary outcome) | 143 | 94.07894737 | (0.903,0.978) |
| 20   | Recruitment | Dates defining the periods of recruitment and follow-up | 123 | 80.92052625 | (0.747,0.872) |
| 21   | Baseline data | A table showing baseline demographic and clinical characteristics for each group | 130 | 85.52631579 | (0.799,0.911) |
| 22   | Intent-to-treat analysis | Number of patients in each group included in each analysis and whether patients were analyzed according to the group to which they were randomly assigned | 19 | 12.5 | (0.072,0.178) |
| 23   | Outcomes measures | For each primary and secondary outcome, a summary of results for each group, the estimated effect size and its precision (e.g., 95% CI) are provided | 124 | 81.57894737 | (0.754,0.877) |
| 24   | Ancillary analyses | Results of subgroup analyses and adjusted analyses, distinguishing prespecified from exploratory | 78 | 51.31578947 | (0.434,0.593) |
| 25   | Adverse event classification | Description of all important adverse events in each group, with classification | 144 | 94.73684211 | (0.912,0.983) |
| 26   | Registration | Presentation of the registration number and name of trial registry | 73 | 48.02631579 | (0.401,0.560) |
| 27   | Protocol | Where the full trial protocol can be accessed | 65 | 42.76315789 | (0.349,0.506) |
| 28   | Funding | Sources of funding and other support | 112 | 73.68421053 | (0.667,0.807) |
revision are generally poorly reported, compared with the 2001 CONSORT statement. In addition, some common OQS project reports in 2010/2001 were neither uniform nor complete (for example, blinding and randomization were implemented; Table 2). With the lack of information, the explanation would be harder and more complicated, thus some key methodological factors and other low-quality reports may even potentially cause misguided consequences.

However, the reporting quality of key methodology projects is also not ideal. With the occasional neglect of some detailed elements and the word limit of one report, it is inevitable for readers to insufficiently understand the whole intention of the author and commentator. For published studies, enough descriptions of major methodological measures are usually lacking, such as the use of allocation concealment in human trials and blindness, in addition, the individual studies are small in scale, so they are vulnerable to a lack of motivation, impairing the effectiveness and usefulness of published studies. Considering that many authors are clinicians, they might consider the clinical features of randomized controlled trials as more interesting indices instead of methodology. Actually, some methods that are not reported in publications are often sufficiently carried out. The insufficiency of the data for these items may present intentional focus rather than a deficient design. In addition, reports on other important issues are unsatisfactory. Under joint projects, future publications need to improve the quality of reporting.

Several methods can promote the quality of reports: increasing compliance with spouses, training, or improving the quality of reporting. Training should be focused on these areas that correspond to poor quality reporting of projects. In this study, CONSORT has not been adopted in some journals. More journal-approved spouses should be encouraged to improve trial reports. It also helps to make the current CONSORT statement more user friendly.

In order to make the article more comprehensive, we adopted many quality evaluation articles to evaluate the index of RCT to complete our article. For example, we used the OQS scoring method used in some quality evaluation articles, as well as all the entries in the 28 CONSORT statements in some quality evaluation articles. Compared with other quality evaluation articles, our article is more comprehensive and advanced.

In conclusion, the overall reporting quality of RCTs including adverse event reporting score, key methodological factors and endpoints on immunotherapy in lung cancer are not ideal. Investigators should pay more attention to CONSORT projects when designing and reporting trials. Additionally, editors and peer reviewers also need to be more scrutinizing and diligent.

Acknowledgments
Support for the study was provided by Beijing Hope Run Special Fund of Cancer Foundation of China (LC2020B09 to Dr Jiachen Xu), the Special Research Fund for Central Universities, Peking Union Medical College (3332021029 to Dr Jiachen Xu), the National Natural Sciences Foundation (81871889 and 82072586 to Dr Zhijie Wang) and Beijing Natural Science Foundation (7212084 to Dr Zhijie Wang).

Conflict of Interest
All authors declare no conflict of interests.

ORCID
Jianchun Duan https://orcid.org/0000-0003-1479-2304
Jie Wang https://orcid.org/0000-0002-5602-0487
Jiachen Xu https://orcid.org/0000-0003-4565-6364

References
1. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17:299–308.
2. Arrieta O, Barrón F, Ramírez-Tirado LA, Zatarain-Barrón ZL, Cardona AF, Díaz-Garcia D, et al. Efficacy and safety of Pembrolizumab plus Docetaxel vs Docetaxel alone in patients with previously treated advanced non–small cell lung cancer. JAMA Oncol. 2020;6:856–864.
3. Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018;19:1468–79.
4. Bedikian AY. Prospective evaluation of thymosin fraction V immunotherapy in patients with non-small cell lung cancer receiving vindesine, doxorubicin, and cisplatin(VAP) chemotherapy. Hagerstown, MD: American journal of clinical oncology; 1984.
5. Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6:e132–43.
6. Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, et al. Patient-reported outcomes in OAK: a phase III study of Atezolizumab versus Docetaxel in advanced non-small-cell lung cancer. Clin Lung Cancer. 2018;19:441–9. e444.
7. Butts C, Maksymiuk A, Goss G, Soulières D, Marshall E, Cormier Y, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol. 2011;137:1337–42.
8. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krazowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:59–68.
9. Chen D, Menon H, Verma V, Guo C, Ramapriyan R, Barsoumian H, et al. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials. J Immunother Cancer. 2020;8:1–7.
10. Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creetan BC, et al. Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. Cancer Immuno Therapeut. 2018;68:517–27.
11. Ciuleanu T, Socinski MA, Obasaju C, Luft AV, Szczesna A, Szafratis W, et al. Efficacy and safety of Necitumumab continuation therapy in the phase III SQUIRE study of patients with stage IV squamous non-small-cell lung cancer. Clin Lung Cancer. 2018;19:130–8. e132.

12. Edelman MJ, Redman MW, Albain KS, EC MG, Rafique NM, Petro D, et al. SWOG S1400C (NCT02154490)- a phase II study of Palbociclib for previously treated cell cycle gene alteration-positive patients with stage IV squamous cell lung cancer (lung-MAP sub-study). J Thorac Oncol. 2019;14:1853–9.

13. Engel-Riedel W, Lowe J, Mattson P, Richard Trout J, Huhn RD, Gargano M, et al. A randomized, controlled trial evaluating the efficacy and safety of BET1H67 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small-cell lung cancer. J Immunother Cancer. 2018;6:16.

14. Fox RM. A randomized study of adjuvant immunotherapy with levamisole and corynebacterium parvum in operable non-small cell lung cancer. 2006.

15. Richards F I. Combination Chemotherapy with and without the Methanol-Extracted Residue of Bacillus Calmette-Guerin (MER) in Extensive Non-Small-Cell Lung Cancer. 1981.

16. Garcia B, Reninger E, da la Torre A, Leonard I, Martinez R, Viada C, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibody is related to better survival in advanced non-small cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res. 2008;14:840–6.

17. Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász É, Ramlaú R, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015;51:2321–9.

18. Giaccone G, Debruyn E, Filip E, Chapman PB, Grant SC, Millward M, et al. Phase III study of adjuvant vaccination with Becv2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva study). J Clin Oncol. 2005;23:6854–64.

19. Goldman JW, Dworkin M, Chen Y, Reimmuth N, Hotta K, Tzukhlin D, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51–65.

20. Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, Cobo M, et al. Clinical activity of a hitrt (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial. Br J Cancer. 2020;122:1461–6.

21. Holmes EC. A randomized comparison of the effects of adjuvant therapy on resected stage II and III non-small cell carcinoma of the lung. Ann Surg. 1985;202:335–41.

22. Kallas EG, Peciosco AR, Palacios R, Thomé B, Braga PE, Vanni T, et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2b trial. Lancet Oncol. 2020:26:1854–68.

23. Albersheim J, Smith DW, Pariser JJ, Dahm P. The reporting quality of randomized controlled trials and experimental animal studies for urethralplasty. World J Urol. 2020;26:777–2683. https://doi.org/10.1007/s00345-020-03501-8

24. Kazandjian D, Suzman DL, Blumenthal G, Mushit S, He K, Libeg M, et al. FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21:634–42.

25. Kimura H, Matsui Y, Ishikawa A, Nakajima T, Izasa T. Randomized controlled phase III trial of adjuvant chemotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer. Cancer Immunol Immunother. 2018;67:1231–8.

26. Kimura H, Matsui Y, Ishikawa A, Nakajima T, Yoshino M, Sakairi Y. Randomized controlled phase III trial of adjuvant chemotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer. Cancer Immunol Immunother. 2015;64:51–9.

27. Kimura H. Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. 1995.

28. Kimouchi T, Sakamoto J, Tsukamoto T, Akaza H, Kubota Y, Osono S, et al. Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis. J Cancer Res Clin Oncol. 2006;132:499–504.

29. Liu SW, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodis FS, et al. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer. 2018;101:114–22.

30. Maio M, Scherpereel A, Calabró L, Aerts J, Perez SC, Beerz A, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18:1261–73.

31. Melosky B, Juergens R, Hirsh V, McLeod D, Leighn L, Tsao MS, et al. Amplifying outcomes: checkpoint inhibitor combinations in first-line non-small cell lung cancer. Oncologist. 2020;25:64–77.

32. Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, et al. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015;26:1134–42.

33. Neninger Vinagers E, de la Torre A, Osorio Rodriguez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:1452–8.

34. Nio Y, Nagami H, Tamura K, Tsubono M, Nio M, Sato M. Multi-institutional randomized clinical study on the comparative effects of intravitreal chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion. Br J Cancer. 1998:80 775–85.

35. Nokiara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, et al. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 trial in lung cancer). Ann Oncol. 2017;28:2698–706.

36. O'Brien M, Saini A, Smith IE, Webb A, Gregory K, Mendes R, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer. 1998;83:853–7.

37. Oronsy B, Reid TR, Larson C, Caroen S, Quinn M, Burbano E, et al. REPLATINUM. Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. Future Oncol. 2019;15:3427–33.

38. Oronsky B, Reid TR, Larson C, Caroen S, Quinan M, Burbano E, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–39.

39. Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, et al. TGO410 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016;17:212–23.

40. Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, et al. Talactoferrin alfa versus placebo in patients with
refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol. 2013;24:2875–80.
41. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Lévy E, et al. A phase II study of Tg4010 (Mva-Muc1-I12) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008;3:735–44.
42. Ratto GB, Zino P, Mirabelli S, Minuti P, Aquilina R, Fantino G. A randomized trial of adoptive Immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer. 1995;78:244–51.
43. Ridolfi L. Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial. Int J Oncol. 2011;4:39–43.
44. Saka H, Kitagawa C, Ichinose Y, Takenoyama M, Ibata H, Kato T, et al. A randomized phase II study to assess the effect of adjuvant immunotherapy using alpha-GalCer-pulsed dendritic cells in the patients with completely resected stage II-III A non-small cell lung cancer: study protocol for a randomized controlled trial. Trials. 2017;18:429.
45. Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8:822–35.
46. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301.
47. Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiepert E. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist leflutimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study. Ann Oncol. 2013;29:2076–84.
48. Thomas M, Sadjadian P, Kollmeier J, et al. A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. Invest New Drugs. 2017;35:345–58.
49. Twardowski P, Wong JYC, Pal SK, Maughan BL, Frankel PH, Franklin K, et al. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. Cancer Treat Res Commun. 2019;19:100116.
50. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al. Adjuvant MAGE-A3 immunotherapy in resected non– small-cell lung cancer: phase ii randomized study results. J Clin Oncol. 2013;31:2396–403.
51. Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:822–35.
52. Zhang Y, Zhou H, Zhang L. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy; anti-PD-1 or anti-PD-L1? J Immuno Ther Cancer. 2018;6:135–141.
53. Zhong R, Han B, Zhong H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol. 2014;35:987–94.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Du J, Zhang Y, Dong Y, Duan J, Bai H, Wang J, et al. Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer. Thorac Cancer. 2021;12:2732–9, https://doi.org/10.1111/1759-7714.14114